Press release

Siemens Healthineers Annual Shareholders’ Meeting approves all agenda items by a large majority

Annual Shareholders’ Meeting 2022

Published on 15. Februar 2022

  • Shareholders approve dividend of EUR 0.85 per share for fiscal year 2021
  • Supervisory Board bids farewell to Managing Board Member Dr. Christoph Zindel

This year’s Annual Shareholders’ Meeting of Siemens Healthineers AG has approved all agenda items by a large majority. At Tuesday’s virtual meeting, shareholders accepted the recommendation of the Managing Board and Supervisory Board to pay a dividend of EUR 0.85 per share for fiscal year 2021. The actions of the Managing and Supervisory Boards in the past fiscal year were ratified by a large majority.

Supervisory Board Chairman Dr. Ralf P. Thomas spoke on behalf of the Board to thank Dr Christoph Zindel, Managing Board member of Siemens Healthineers since 2019, for his great commitment and achievements over the past years. Dr. Zindel informed the Supervisory Board in September that for private reasons he would not be available for an extension of his Managing Board mandate. Under his lead, the Imaging and Advanced Therapies segments experienced outstanding development. He also made a crucial contribution to initiating Siemens Healthineers’ comprehensive Sustainability Program.

At peak audience, 975 shareholders and their authorized representatives attended the online meeting, with presenters fielding 77 questions.

Siemens Healthineers 2022

Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) pioneers breakthroughs in healthcare. For everyone. Everywhere. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers and its regional companies is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company’s foundation in in-vitro diagnostics, image-guided therapy, in-vivo diagnostics, and innovative cancer care. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers’ ability to provide high-quality, efficient care. In fiscal 2021, which ended on September 30, 2021, Siemens Healthineers, which has approximately 66,000 employees worldwide, generated revenue of €18.0 billion and adjusted EBIT of €3.1 billion. Further information is available at